MEK Inhibitors for Mutated Pancreatic Cancer: Safety, Efficacy, and Combinations

Drs. Elizabeth Auckley, Stephanie Yohay, and Mandana Kamgar of the Medical College of Wisconsin discuss their research on the efficacy of MEK inhibitor-based therapy for metastatic pancreatic ductal adenocarcinoma in this three-part interview.

In this discussion, the efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies, and the use of MEK inhibitors as a promising approach for early- and late-line therapies is discussed.